Vor Biopharma's (VOR) "Outperform" Rating Reaffirmed at Wedbush

Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Wedbush in a research note issued to investors on Thursday, MarketBeat reports.

A number of other research firms also recently commented on VOR. Oppenheimer reaffirmed an "outperform" rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. HC Wainwright restated a "neutral" rating on shares of Vor Biopharma in a research note on Friday, May 9th. Jones Trading downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. JMP Securities reissued a "market perform" rating and issued a $6.00 target price on shares of Vor Biopharma in a report on Friday, May 9th. Finally, Baird R W downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $7.06.

Vor Biopharma Price Performance

Shares of VOR traded up $0.43 on Thursday, reaching $0.99. 263,394,081 shares of the stock traded hands, compared to its average volume of 3,360,289. The stock's 50-day moving average price is $0.35 and its 200-day moving average price is $0.83. The firm has a market cap of $123.09 million, a price-to-earnings ratio of -0.61 and a beta of -0.51. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $1.80.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Vor Biopharma in the first quarter worth $140,000. Goldman Sachs Group Inc. raised its holdings in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma during the 1st quarter worth about $100,000. Money Concepts Capital Corp grew its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after acquiring an additional 26,535 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after acquiring an additional 25,930 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.